In the past week, AYTU stock has gone up by 27.36%, with a monthly gain of 12.50% and a quarterly plunge of -15.62%. The volatility ratio for the week is 9.98%, and the volatility levels for the last 30 days are 8.45% for Aytu BioPharma Inc The simple moving average for the past 20 days is 27.04% for AYTU’s stock, with a -26.37% simple moving average for the past 200 days.
Is It Worth Investing in Aytu BioPharma Inc (NASDAQ: AYTU) Right Now?
The stock has a 36-month beta value of -0.07. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AYTU is 5.99M, and at present, short sellers hold a 1.98% of that float. On May 01, 2025, the average trading volume of AYTU was 34.89K shares.
AYTU) stock’s latest price update
The stock price of Aytu BioPharma Inc (NASDAQ: AYTU) has jumped by 26.17 compared to previous close of 1.07. Despite this, the company has seen a gain of 27.36% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-21 that Company to conduct 1×1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 1:30 p.m. Pacific time (4:30 p.m.
Analysts’ Opinion of AYTU
Many brokerage firms have already submitted their reports for AYTU stocks, with Cantor Fitzgerald repeating the rating for AYTU by listing it as a “Overweight.” The predicted price for AYTU in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on March 30, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AYTU reach a price target of $3. The rating they have provided for AYTU stocks is “Buy” according to the report published on May 29th, 2020.
AYTU Trading at 14.58% from the 50-Day Moving Average
After a stumble in the market that brought AYTU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.84% of loss for the given period.
Volatility was left at 8.45%, however, over the last 30 days, the volatility rate increased by 9.98%, as shares surge +16.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.57% lower at present.
During the last 5 trading sessions, AYTU rose by +27.36%, which changed the moving average for the period of 200-days by -51.61% in comparison to the 20-day moving average, which settled at $1.0627. In addition, Aytu BioPharma Inc saw -20.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AYTU starting from Disbrow Joshua R., who purchase 15,000 shares at the price of $1.30 back on Feb 28 ’25. After this action, Disbrow Joshua R. now owns 86,591 shares of Aytu BioPharma Inc, valued at $19,500 using the latest closing price.
Stock Fundamentals for AYTU
Current profitability levels for the company are sitting at:
- -0.13 for the present operating margin
- 0.67 for the gross margin
The net margin for Aytu BioPharma Inc stands at -0.08. The total capital return value is set at -0.17. Equity return is now at value -18.06, with -4.64 for asset returns.
Based on Aytu BioPharma Inc (AYTU), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at 0.36. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -4.22.
Currently, EBITDA for the company is -1.01 million with net debt to EBITDA at 68.93. When we switch over and look at the enterprise to sales, we see a ratio of -0.15. The receivables turnover for the company is 2.71for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.98.
Conclusion
To sum up, Aytu BioPharma Inc (AYTU) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
